Roche Holdings Ltd ADR (RHHBY)

$57.11 -0.59 (-1.02%)
Market Cap 367.58B
Revenue (ttm) 76.45B
Net Income (ttm) 15.54B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 18.12
Profit Margin 20.33%
Debt to Equity Ratio 1.00
Volume 3,509,200
Avg Vol 2,766,894
Day's Range N/A - N/A
Shares Out 6.37B
Stochastic %K 76%
Beta 0.44
Analysts Sell
Price Target $52.72

Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 41 61 688 88 80
Fax: 41 61 691 00 14
Address:
Grenzacherstrasse 124, Basel, Switzerland
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 20 at 3:50 PM
$SLS @Bcon852 Phase 3 Results / 80th event Could occur at Any Time - it is conceivable, and offers a Slight discount - so possible. -- Pharma's have enough, know enough, Aza+VEN Failed 3 Large Phase 3 Trials, including 2 for AML Remission Maintenance - VIALE-M and VIALE-T both Failed. $ABBV $BMY $RHHBY who conducted the trials, Know Precisely how their Drugs work or don't work for AML Patients IN REMISSION/ they also see the Extended GPS P3 Data, like everyone Else - 54 of 128 Survivors at 2 YEARS - is a miracle for these AML CR2 Transplant Ineligible Patients. - So they May be Willing to Pay Something Reasonably CLose to Angelos 'Max Value' Requirement. -We know SLS is for Sale - we Know there has been buyer interest, we know there are ongoing negotiations and the Last words on the subject from the CEO were " we will let the public know when we have something concrete ". -8k Change of Control GC/CFO options accelerating. - no RSU's - no hiring of commercial team ... and more
0 · Reply
NasdaqKnight
NasdaqKnight Mar. 20 at 3:27 PM
$CCCC | The “Avengers” of targeted protein degradation—MRK, PFE, BIIB, RHHBY all in. 👉If this is helpful to you, tap @NasdaqKnight C4 Therapeutics isn’t a lottery ticket. It’s a platform-backed biotech with an absurd partnership roster. Confirmed collaborations $MRK / $PFE / $BIIB / $RHHBY / Betta — Every major pharma wants access to their TPD platform. This level of multi-party validation is rare in small-cap biotech. Price targets Wells Fargo PT: $10 Bull case: $21 Upside from current levels: 250%+ (even the base case implies a double) M&A angle In a market hungry for de-risked platforms, $CCCC checks every box: differentiated science, marquee partnerships, and a market cap that fits Big Pharma’s acquisition range. This is a legitimate takeout candidate. ⚠️ Risks exist (clinical data, cash runway), but when you see this lineup of partners, you know institutional due diligence is already priced in.
1 · Reply
DonCorleone77
DonCorleone77 Mar. 19 at 6:54 PM
$SRRK $RHHBY Cantor sees Scholar Rock dominating SMA market after Genentech news Cantor Fitzgerald analyst Eric Schmidt says Roche's (RHHBY) Genentech sent a letter today to the spinal muscular atrophy community that included an update on the development of emugrobart, an anti-myostatin antibody. According to the letter, Genentech made the decision not to advance emugrobart. Cantor says emugrobart was trailing Scholar Rock's (SRRK) apitegromab in development by several years, and "offered little in the way of differentiation." The firm now expects apitegromab to have "near complete market share" as the lone muscle-building therapy for SMA patients. It continues to view apitegromab's FDA approval as a likely 2026 event. The firm sees multi-billion dollar potential for the drug and notes Scholar Rock continues to be a top pick.
1 · Reply
Quantumup
Quantumup Mar. 19 at 6:30 PM
Cantor reiterated $SRRK Top Pick; Overweight $RHHBY $BIIB LLY $NVO IONS $PTCT Here's what Cantor said: https://x.com/Quantumup1/status/2034697600415260772?s=20
0 · Reply
Quantumup
Quantumup Mar. 18 at 2:27 PM
Jefferies⬆️ $CTMX's PT to $16 from $8 and reiterated at Buy rating. $ABBV $RHHBY Jefferies said in its note:::Stock has retraced by ~20% from +~45% at D1 following expanded Ph1a data which we view as a sig de-risking readout given a novel masked EpCAM ADC (NOTE). We think mgmt clarity and further data disclosure could address investors' debate/ curiosity, mostly driven by smaller N/ short follow-up, particularly at dose optimization. We note our view below and bull/ bear views (Chart 1). We see a buying oppty here with a rare ADC asset capable of generating an ~$1B+ opportunity in 3L+ mCRC alone, with potential ~$5B+ as into 1/2L, and possible expansion into a wide range of solid tumors with high EpCAM expression (e.g., gastric, ovarian, lung, breast).
0 · Reply
DmcMouse
DmcMouse Mar. 17 at 5:22 PM
$LMDX $LMDXF $RHHBY ElectraDx UK Ltd So let’s get this straight… Roche walks away with the tech. ElectraDx UK Ltd pops up with the people. Billions in technology… still being used. And the shareholders who funded it? Wiped out. How convenient.
3 · Reply
TradeTracs
TradeTracs Mar. 17 at 4:38 PM
Roche is revolutionizing drug discovery 🚀 They launched an AI factory with 2,176 Nvidia Blackwell GPUs, part of over 3,500 in total, the largest for any pharma company. Using Nvidia's BioNeMo and Omniverse, Roche connects experiments with AI models, accelerating breakthroughs that once took years. This 2023 partnership is changing the game. $NVDA $RHHBY #Roche #Blackwell #GPU #AI
0 · Reply
DonCorleone77
DonCorleone77 Mar. 17 at 11:37 AM
$NVDA $RHHBY Roche deploying more than 3,500 Nvidia Blackwell GPUs Roche (RHHBY) is deploying more than 3,500 NVIDIA (NVDA) Blackwell GPUs across hybrid cloud and on-premises environments in the U.S. and Europe, expanding on an existing collaboration to turn AI and accelerated computing into a core operating capability across its pharmaceutical and diagnostics businesses, the company said Monday. "We're excited to innovate at the intersection of science and technology to accelerate drug and diagnostic solutions development," said Wafaa Mamilli, chief digital and technology officer at Roche. "With high-quality data and smarter AI, we will be able to leverage those insights both in pharma as well as in our diagnostic divisions."
0 · Reply
SKVT
SKVT Mar. 17 at 5:56 AM
$RHHBY roche will make a big announcement in AD/PD 2026. Prasinezumab trial 3 will be a game changer in parkinson's disease. $PRTA
1 · Reply
The_Blue_Print
The_Blue_Print Mar. 16 at 7:15 PM
$RHHBY making the turn. $100 stock eventually
0 · Reply
Latest News on RHHBY
No data available.
67X_ROI_Q1_2026
67X_ROI_Q1_2026 Mar. 20 at 3:50 PM
$SLS @Bcon852 Phase 3 Results / 80th event Could occur at Any Time - it is conceivable, and offers a Slight discount - so possible. -- Pharma's have enough, know enough, Aza+VEN Failed 3 Large Phase 3 Trials, including 2 for AML Remission Maintenance - VIALE-M and VIALE-T both Failed. $ABBV $BMY $RHHBY who conducted the trials, Know Precisely how their Drugs work or don't work for AML Patients IN REMISSION/ they also see the Extended GPS P3 Data, like everyone Else - 54 of 128 Survivors at 2 YEARS - is a miracle for these AML CR2 Transplant Ineligible Patients. - So they May be Willing to Pay Something Reasonably CLose to Angelos 'Max Value' Requirement. -We know SLS is for Sale - we Know there has been buyer interest, we know there are ongoing negotiations and the Last words on the subject from the CEO were " we will let the public know when we have something concrete ". -8k Change of Control GC/CFO options accelerating. - no RSU's - no hiring of commercial team ... and more
0 · Reply
NasdaqKnight
NasdaqKnight Mar. 20 at 3:27 PM
$CCCC | The “Avengers” of targeted protein degradation—MRK, PFE, BIIB, RHHBY all in. 👉If this is helpful to you, tap @NasdaqKnight C4 Therapeutics isn’t a lottery ticket. It’s a platform-backed biotech with an absurd partnership roster. Confirmed collaborations $MRK / $PFE / $BIIB / $RHHBY / Betta — Every major pharma wants access to their TPD platform. This level of multi-party validation is rare in small-cap biotech. Price targets Wells Fargo PT: $10 Bull case: $21 Upside from current levels: 250%+ (even the base case implies a double) M&A angle In a market hungry for de-risked platforms, $CCCC checks every box: differentiated science, marquee partnerships, and a market cap that fits Big Pharma’s acquisition range. This is a legitimate takeout candidate. ⚠️ Risks exist (clinical data, cash runway), but when you see this lineup of partners, you know institutional due diligence is already priced in.
1 · Reply
DonCorleone77
DonCorleone77 Mar. 19 at 6:54 PM
$SRRK $RHHBY Cantor sees Scholar Rock dominating SMA market after Genentech news Cantor Fitzgerald analyst Eric Schmidt says Roche's (RHHBY) Genentech sent a letter today to the spinal muscular atrophy community that included an update on the development of emugrobart, an anti-myostatin antibody. According to the letter, Genentech made the decision not to advance emugrobart. Cantor says emugrobart was trailing Scholar Rock's (SRRK) apitegromab in development by several years, and "offered little in the way of differentiation." The firm now expects apitegromab to have "near complete market share" as the lone muscle-building therapy for SMA patients. It continues to view apitegromab's FDA approval as a likely 2026 event. The firm sees multi-billion dollar potential for the drug and notes Scholar Rock continues to be a top pick.
1 · Reply
Quantumup
Quantumup Mar. 19 at 6:30 PM
Cantor reiterated $SRRK Top Pick; Overweight $RHHBY $BIIB LLY $NVO IONS $PTCT Here's what Cantor said: https://x.com/Quantumup1/status/2034697600415260772?s=20
0 · Reply
Quantumup
Quantumup Mar. 18 at 2:27 PM
Jefferies⬆️ $CTMX's PT to $16 from $8 and reiterated at Buy rating. $ABBV $RHHBY Jefferies said in its note:::Stock has retraced by ~20% from +~45% at D1 following expanded Ph1a data which we view as a sig de-risking readout given a novel masked EpCAM ADC (NOTE). We think mgmt clarity and further data disclosure could address investors' debate/ curiosity, mostly driven by smaller N/ short follow-up, particularly at dose optimization. We note our view below and bull/ bear views (Chart 1). We see a buying oppty here with a rare ADC asset capable of generating an ~$1B+ opportunity in 3L+ mCRC alone, with potential ~$5B+ as into 1/2L, and possible expansion into a wide range of solid tumors with high EpCAM expression (e.g., gastric, ovarian, lung, breast).
0 · Reply
DmcMouse
DmcMouse Mar. 17 at 5:22 PM
$LMDX $LMDXF $RHHBY ElectraDx UK Ltd So let’s get this straight… Roche walks away with the tech. ElectraDx UK Ltd pops up with the people. Billions in technology… still being used. And the shareholders who funded it? Wiped out. How convenient.
3 · Reply
TradeTracs
TradeTracs Mar. 17 at 4:38 PM
Roche is revolutionizing drug discovery 🚀 They launched an AI factory with 2,176 Nvidia Blackwell GPUs, part of over 3,500 in total, the largest for any pharma company. Using Nvidia's BioNeMo and Omniverse, Roche connects experiments with AI models, accelerating breakthroughs that once took years. This 2023 partnership is changing the game. $NVDA $RHHBY #Roche #Blackwell #GPU #AI
0 · Reply
DonCorleone77
DonCorleone77 Mar. 17 at 11:37 AM
$NVDA $RHHBY Roche deploying more than 3,500 Nvidia Blackwell GPUs Roche (RHHBY) is deploying more than 3,500 NVIDIA (NVDA) Blackwell GPUs across hybrid cloud and on-premises environments in the U.S. and Europe, expanding on an existing collaboration to turn AI and accelerated computing into a core operating capability across its pharmaceutical and diagnostics businesses, the company said Monday. "We're excited to innovate at the intersection of science and technology to accelerate drug and diagnostic solutions development," said Wafaa Mamilli, chief digital and technology officer at Roche. "With high-quality data and smarter AI, we will be able to leverage those insights both in pharma as well as in our diagnostic divisions."
0 · Reply
SKVT
SKVT Mar. 17 at 5:56 AM
$RHHBY roche will make a big announcement in AD/PD 2026. Prasinezumab trial 3 will be a game changer in parkinson's disease. $PRTA
1 · Reply
The_Blue_Print
The_Blue_Print Mar. 16 at 7:15 PM
$RHHBY making the turn. $100 stock eventually
0 · Reply
scotttrader213
scotttrader213 Mar. 16 at 4:18 PM
$RHHBY bounced off of 50 mark, nicely
0 · Reply
Quantumup
Quantumup Mar. 16 at 1:52 PM
Oppenheimer⬆️ $CTMX to $12 from $10, reiterated at an OP rating, and says that data continues to support its view that CX-2051 could be a game-changer after CytomX reported updated expansion data. $ABBV $RHHBY Oppenheimer said—CytomX reported updated expansion data from CX-2051 (varsetatug masetecan) that, in our view, handily exceeded even the upside case outline in our recent scenario analysis. Confirmed ORR reached 32% at the 10 mg/kg dose with median PFS of 7.1 months, while the 8.6 mg/kg cohort showed a 20% ORR and 6.8 month PFS. Safety also improved with optimized prophylaxis. Grade 3 diarrhea fell to 10% in dose-optimization cohorts treated with prophylactic loperamide and budesonide, supporting the hypothesis raised in our KOL work that Gl tox would be manageable. These data continue to support our view that CX-2051 could be a game-changer for patients with colon cancer, and may have room to move up the treatment paradigm. Increasing PT to $12 (from $10). Reiterate Outperform.
0 · Reply
Quantumup
Quantumup Mar. 16 at 12:20 PM
JPMorgan⬆️ $SRRK's PT to $50 from $47AND reiterated at an Overweight rating. $RHHBY $BIIB LLY NVO JPMorgan said in its note—We continue to recommend SRRK into the balance of 2026 and believe apiteg romab should be approved with a broad label (2yo+) and see a strong launch in SMA given the clinical data and high unmet need. We see the drug growing to be a >$2B product in worldwide sales over time. Notably, we recently attended the Muscular Dystrophy Association (MDA) conference (Mar. 8-11, 2026; Orlando, FL) in-person and had the opportunity to attend several sessions focused on spinal muscular atrophy (SMA) where KOLs emphasized the urgency to diagnose and treat early (i.e., time is muscle); we heard in our conversations with KOLs that the focus for apitegromab's use, if approved, will be on patients who are showing functional decline despite treatment with currently available SMN-targeted therapies.
0 · Reply
scotttrader213
scotttrader213 Mar. 16 at 11:52 AM
$RHHBY has received CE Mark approval for its Elecsys Apolipoprotein E4 biomarker test – the first in-vitro diagnostic (IVD) immunoassay to identify the presence of the ApoE4 gene variant in the bloodstream.
0 · Reply
toyboy67
toyboy67 Mar. 15 at 9:56 AM
$RHHBY I have been taking Evrysdi for quite some time now, and my total treatment costs (Spinraza/Evrysdi) already exceed $2 million USD. I have been in inpatient rehabilitation for 10 weeks and am loading my muscles daily. The healthy muscles are getting stronger, and the affected muscle groups are being reactivated and starting to work again. I am reaching milestones that I was not able to achieve before. This motivates me to keep going. The rehab costs approximately $8,000–$10,000 USD per month, but I have top therapists who push me, monitor me, and observe me closely. Leg press, butterfly, cable pulls and more are all part of it. According to the senior and chief physicians in Germany, I am the only person with this condition who is really going all in and fully committed.
1 · Reply
JuggernautRaider
JuggernautRaider Mar. 14 at 11:10 PM
$ALT I agree that NVO and $RHHBY would be likely acquirers following the phase 2 for AUD at the higher 2.4mg dose - ESPECIALLY if the weight loss improves upon the 8% seen at the 1.8mg dose in the Ph2B trial. Also $AZ and $PFE . I don’t think LLY is as likely. They are a Juggernaut across the board 🏃‍♂️
0 · Reply
scotttrader213
scotttrader213 Mar. 13 at 4:40 PM
$RHHBY looking to add under 48
0 · Reply
Quantumup
Quantumup Mar. 13 at 3:09 PM
BofA⬆️ Mineralys' PT to $51 from $46 and reiterated at a Buy, separately Stifel on $MLYS said: We reiterate our Buy rating, $52 TP. $AZN $ALNY - $RHHBY $NVS Here's what else Stifel had to say: https://x.com/Quantumup1/status/2032473479035936901?s=20
0 · Reply
truehealthvalue
truehealthvalue Mar. 12 at 9:43 PM
$RHHBY take a look at $ELTX CEO comment 30’ ago: “Fewer disease progressions and deaths than projected to date have been observed in the ongoing 2:1 randomized Phase 2 AMPLIFY-7P trial” The previous comment by Elicios CEO is key: he is telling you that the results are guaranteed to be good, better than anything currently available. This company could be one of the best investments in the history of biotechnology. It is certainly worth much more than its current valuation. I will Increase my position
0 · Reply
Quantumup
Quantumup Mar. 12 at 3:31 PM
Wolfe Research on $CELC (Outperform; $110) said, Competitor's Data Unchanged; Maintain OP on CELC $RLAY $RHHBY $LLY $BBOT BGNE NVS Here's what else Wolfe Research had to say in its note to investors: https://x.com/Quantumup1/status/2032116442045231572?s=20
0 · Reply
Quantumup
Quantumup Mar. 10 at 1:27 PM
Needham⬆️the PT on $CELC to $122 from $95 and reiterated at a Buy $RLAY $RHHBY LLY $AZN $NVS PFE Needham said—Celcuity announced yesterday that the NDA for gedatolisib received priority review, with a PDUFA date of July 17, 2026. Additionally, the company announced the publication of results from the PIK3CA WT cohort of the VIKTORIA-1 study evaluating gedatolisib-based regimens in HR+/HER2- mBC in the Journal of Clinical Oncology. The detailed results were consistent with prior disclosures, while demonstrating a trending benefit in OS. Given the potential for an earlier approval, we reiterate our Buy Rating and are increasing our Price Target from $95 to $122.
0 · Reply
scotttrader213
scotttrader213 Mar. 10 at 12:41 PM
$RHHBY Roche moved five drugs from midstage to late-stage trials last year and all five sit in its most promising pipeline bucket, with peak sales estimated at above 3 billion Swiss francs,
0 · Reply